LGVN Q2 2021 Earnings — Longeveron Inc. Revenue & Financial Results | Market Cap Arena

LGVNLongeveron Inc.

$18M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$489,000-44.2% YoY

Gross Profit

$208,00042.5% margin

Operating Income

-$5M-1035.2% margin

Net Income

-$5M-1024.5% margin

EPS (Diluted)

$-2.64

QoQ Revenue Growth

+30.1%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$30M

Total Liabilities

$5M

Stockholders' Equity

$25M

Cash & Equivalents

$17M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$489,000	$876,000	-44.2%
Gross Profit	$208,000	$112,000	+85.7%
Operating Income	-$5M	-$1M	-312.9%
Net Income	-$5M	-$1M	-312.0%